Skip to main content
OpenTrials
Completed

NCT Number: NCT02591121

Procalcitonin Test Reference Range Determination

Prospective, single-centre study in healthy volunteers to establish a reference range for the RAMP Procalcitonin (PCT) test. The primary objective of this study is to establish the reference range for measurement of PCT levels using the RAMP Procalcitonin test.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Mt. Sinai Hospital

Toronto, Ontario, Canada

About this study

Healthy volunteers who meet eligibility criteria and have provided informed consent will be enrolled in this study. Each participant will be required to donate 1 blood sample via standard venipuncture into an EDTA (lavender top) tube for testing on one occasion. The maximum trial duration for each participant is one visit/occasion. Sample collection will take place within a single clinical session. The maximum trial duration for each participant is one clinic session.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Apparently healthy (as determined by a subject questionnaire) males or females, of any race
  • >18 years of age
  • Willing to voluntarily agree to sign a consent form

Exclusion criteria

  • Meets the definition for one or more of Systematic Inflammatory Response Syndrome (SIRS), Sepsis, Severe Sepsis, Septic Shock and/or Multiple Organ Dysfunction Syndrome (MODS) as defined by The American College of Chest Physicians (ACCP) and the Society of Critical Care Medicine (SCCM) consensus conference in 1992.
  • Current diagnosis, or history, of any underlying major medical condition such as heart disease, hypertension/hypotension, stroke, renal disease, chronic obstructive pulmonary disorder, diabetes, bleeding disorders, hypercalcitoninemia, HIV, etc.
  • Bacterial, fungal or malaria infection within previous 12 months
  • Have experienced or undergone trauma, surgery, cardiac shock and/or a burn within previous 3 months
  • Current diagnosis of cancer and/or has undergone Immunotherapy which stimulates cytokines in the previous 12 months
  • Hospitalization (for >24 hours) within previous 3 months
  • Currently pregnant or nursing a child
  • Unable, or unwilling, to provide required blood sample for testing
  • Non-compliance to the protocol or inclusion criteria
  • Investigator believes subject is unsuitable for inclusion in the trial (i.e. has major condition(s) or other reason(s) that could limit their ability to participate in the study; or impact the scientific integrity of the study)

Treatment and study plan

Primary outcomes

  1. Procalcitonin value for healthy reference subjects

    Time frame: Subjects will be followed for duration of one blood draw from one visit only; study enrollment will occur over 21 days.

    Procalcitonin value for each subject will be determined within 2 hours of phlebotomy. At study completion all data obtained will be compiled and a 95th percentile value determined.

Sponsors and collaborators

Lead sponsor

Response Biomedical Corp.

Industry

Registry information

Official study title

Clinical Evaluation To Determine The Expected Values Distribution Of Procalcitonin For The RAMP® Procalcitonin Test In A Healthy Reference Population (PRO-H)

Acronym: PRO-H

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Oct 29, 2015
Registry last updated
Nov 16, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.